	Charles River Laboratories announced on June 27, 2016 that it has acquired Blue Stream Laboratories, an analytical contract research organization (CRO) supporting the development of complex biologics and biosimilars. This acquisition will combine Blue Stream and Charles River’s existing discovery, safety assessment, and biologics capabilities, Charles River said in a 

 Blue Stream is located in Woburn, Massachusetts, and is recognized for its work in structural and function protein characterization programs, the development and validation of assays for cGMP lot release, and stability programs.

	“Our continued investment in expanding our biologics portfolio, through the development of new assays and capabilities, has enabled us to provide a broader testing solution for our clients,” James C. Foster, chairman, president, and CEO of Charles River said in a statement. “This investment is particularly important now, when the number of biologic and biosimilar drugs in development is increasing. The acquisition of Blue Stream will meaningfully enhance the ability of our Biologic Testing Solutions business to compete effectively in this high-growth market segment.”

PharmTech News

Supplier News

PTSM: Pharmaceutical Technology Sourcing and Management-07-06-2016

Charles River acquired Blue Stream Laboratories, an analytical contract research organization.